CRO services for Diabetes Mellitus

Diabetes mellitus is a chronic progressive disease associated with dysfunction and loss of β cells. Glycemic control alone is not sufficient to stop the disease progression, and novel approaches beyond glycemic control are also required for the treatment of diabetes and its complications.

KK-Ay, neonatal STZ, ob/ob and db/db mice are the most common models to assess the in vivo activity of new anti-diabetic agents. These models are recommended by the U.S. FDA and/or the Japan MHLW to use for developing new anti-diabetic agents.

SMC, a Tokyo-based biotech company known as the leading nonclinical CRO for nonalcoholic steatohepatitis-hepatocellular carcinoma, now provides pharmacology study service using established diabetes mouse models. Our expertise achieved in diabetes-based steatohepatitis research can also be applied to diabetes R&D.

For more information, please contact us below.

Phone: +81-3-6715-9101 / E-mail: info@smclab.co.jp / Website: www.smclab.co.jp